Form 4: Sutro Biopharma COO Jane Chung Reports Stock Transactions
SEC Form 4 Filing
Jane Chung, COO of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On August 9, 2024, Jane Chung, the President and COO of Sutro Biopharma, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
- 18,750 shares were acquired through the vesting of RSUs.
- 6,689 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement at a price of $3.12 per share.
- Following these transactions, Chung directly owns 54,262 shares of common stock and 18,750 RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 08/09/2022 | Initial vesting date of RSUs, with 1/4th of the total award vesting annually thereafter. |
| 08/09/2024 | Date of the reported transactions: RSU vesting and tax withholding. |
| 08/09/2025 | Expiration date of the Restricted Stock Units. |
| 08/13/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.